SWOG clinical trial number
SWOG-9109
Neoadjuvant Zoladex and Flutamide in Bulky and Non-Bulky Clinical Stage C Carcinoma of the Prostate, Phase II
Closed
Phase
Accrual
100%
Published
Abbreviated Title
Local Prostate
Activated
12/01/1993
Closed
10/15/1996
Research committees
Genitourinary Cancer
Treatment
Goserelin Acetate
Publication Information Expand/Collapse
2012
2002
Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5 year follow-up, phase II SWOG study 9109
2001
Neoadjuvant zoladex and flutamide in bulky and non-bulky clinical stage C carcinoma of the prostate
Other Clinical Trials
SWOG Clinical Trial Number
S2210
S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
S2200
S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
8%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA8185
Phase II Study of Bladder-SparIng ChemoradiatioN with MEDI4736 (Durvalumab) in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE)
Research Committee(s)
Genitourinary Cancer
Activated
05/01/2021
Open
Phase